

FILLETED

Company registration number: 6914840

Total Pharma Ltd

Unaudited financial statements

31 March 2017

SATURDAY



A6LVD110

A11

23/12/2017

#388

COMPANIES HOUSE

Total Pharma Ltd
Statement of financial position
31st March 2017

	Note	2017 £	2016 £
Fixed assets			
Tangible assets	4	23	31
		23	31
Current assets			
Debtors		27,876	23,935
Cash at bank and in hand		4,745	10,323
		32,621	34,258
Creditors: amounts falling due within one year		(5,668)	(5,631)
Net current assets		26,953	28,627
Total assets less current liabilities		26,976	28,658
Net assets		26,976	28,658
Capital and reserves			
Called up share capital	5	2	2
Profit and loss account		26,974	28,656
Shareholders funds		26,976	28,658

For the year ending 31st March 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The shareholders have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.

The notes on pages 3 to 5 form part of these financial statements.

Total Pharma Ltd

Statement of financial position (continued)
31st March 2017

These financial statements were approved by the board of directors and authorised for issue on 15th December 2017, and are signed on behalf of the board by:

A handwritten signature in black ink, appearing to read 'S. Scott', written in a cursive style.

Mr Stephen Scott
Director

Company registration number: 6914840

The notes on pages 3 to 5 form part of these financial statements.

Total Pharma Ltd

Notes to the financial statements Year ended 31st March 2017

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Belvoir House, 1 Rous Road, Newmarket, Suffolk, CB8 8DH.

2. Statement of compliance

These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Transition to FRS 102

The entity transitioned from previous UK GAAP to FRS 102 as at 1st April 2015. Details of how FRS 102 has affected the reported financial position and financial performance is given in note 8.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are initially recorded at cost, and is subsequently stated at cost less any accumulated depreciation and any accumulated impairment losses.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Fittings fixtures and equipment	- 25%	reducing balance
---------------------------------	-------	------------------

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Total Pharma Ltd

Notes to the financial statements (continued)
Year ended 31st March 2017

4. Tangible assets

	Fixtures, fittings and equipment £	Total £
Cost		
At 1st April 2016 and 31st March 2017	200	200
Depreciation		
At 1st April 2016	169	169
Charge for the year	8	8
At 31st March 2017	177	177
Carrying amount		
At 31st March 2017	23	23
At 31st March 2016	31	31

**5. Called up share capital
Issued, called up and fully paid**

	2017		2016	
	No	£	No	£
Ordinary shares of £ 1.00 each	2	2	2	2

6. Directors advances, credits and guarantees

During the year the company entered into the following guarantees on behalf of its director:

	Maximum liability		Amount paid/liability incurred	
	2017	2016	2017	2016
	£	£	£	£
Mr Stephen Scott	5,980	962	5,018	-

7. Related party transactions

At 31 March 2017, a balance of £21,655 was due from S. & J. Project Management Ltd. This is a company in which the director Mr Stephen Scott is materially interested as a director and shareholder. The amount due is interest free and payable on demand.

Total Pharma Ltd

Notes to the financial statements (continued)
Year ended 31st March 2017

8. Transition to FRS 102

These are the first financial statements that comply with FRS 102. The company transitioned to FRS 102 on 1st April 2015.

Reconciliation of equity

No transitional adjustments were required.

Reconciliation of profit or loss for the year

No transitional adjustments were required.